Jessica Coleman, MD
Nephrology · Beaufort, SCNPI 1376785394
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.8%. 2025 is the largest year on record at $267,189, 4.5 times the $60,018 reported in 2019. Among nephrology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,668 payments — averaging $557.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$203K
- Travere Therapeutics, Inc.$186K
- Bayer$116K
- ANI Pharmaceuticals, Inc.$73K
- Akebia Therapeutics Inc$52K
- Vifor Pharma, Inc.$51K
- plus $249K from 27 others
What the payments were for
- Consulting fees$163,02718%
- Speaking & faculty fees$537,02258%
- Travel & lodging$196,59321%
- Food & beverage$32,3203%
- Education$6740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 321 | $202,613 |
| Travere Therapeutics, Inc. | 351 | $186,141 |
| Bayer | 123 | $115,926 |
| ANI Pharmaceuticals, Inc. | 116 | $73,002 |
| Akebia Therapeutics Inc | 99 | $51,790 |
| Vifor Pharma, Inc. | 107 | $51,263 |
| Amgen(2 entities) | 119 | $49,749 |
| GSK | 40 | $39,435 |
| Otsuka America Pharmaceutical, Inc. | 119 | $39,230 |
| Calliditas Therapeutics US Inc. | 61 | $38,002 |
| Fresenius USA Marketing, Inc. | 61 | $34,483 |
| Novartis | 39 | $22,358 |
| Ardelyx, Inc. | 21 | $18,586 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $1,792 |
| Sanofi | 5 | $1,579 |
| Johnson & Johnson | 2 | $1,315 |
| Mallinckrodt Hospital Products Inc. | 31 | $1,034 |
| Aurinia Pharma U.S., Inc. | 14 | $266 |
| OPKO Pharmaceuticals, LLC | 11 | $191 |
| Nxstage Medical, Inc. | 3 | $179 |
| Mallinckrodt Enterprises LLC | 3 | $159 |
| Corcept Therapeutics | 7 | $147 |
| One Lambda, Inc. | 1 | $128 |
| Chiesi USA, Inc. | 2 | $52 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Abbott | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Shield Therapeutics Inc | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$106,501
- FARXIGA$92,265
- LOKELMA$87,164
- PURIFIED CORTROPHIN GEL$70,262
- Filspari$63,068
- Vafseo$46,632
- KRYSTEXXA$46,005
- Veltassa$40,098
- TARPEYO$37,204
- JYNARQUE$34,105
- Korsuva$27,418
- JESDUVROQ$22,069
- Fabhalta$20,509
- XPHOZAH 30 MG$18,317
- LEQVIO$6,498
- Velphoro$6,216
- FABRAZYME$1,516
- INVOKANA$1,315
- SAMSCA$1,301
- ACTHAR$344
How this compares
$929,636 in reported general payments places this provider in the 95th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 14 | $475,448 |
| XphozahTenapanor Hcl | 66 | $320,043 |
| VelphoroSucroferric Oxyhydroxide | 77 | $217,629 |
| KerendiaFinerenone | 186 | $211,869 |
| FarxigaDapagliflozin Propanediol | 186 | $211,813 |
| VeltassaPatiromer Calcium Sorbitex | 55 | $83,453 |
| LokelmaSodium Zirconium Cyclosilicate | 71 | $79,539 |
| RayaldeeCalcifediol | 16 | $49,013 |
| JardianceEmpagliflozin | 26 | $35,576 |
| AuryxiaFerric Citrate | 31 | $30,932 |
| Sevelamer Carbonate | 44 | $13,874 |
| Cinacalcet Hcl | 22 | $10,686 |
| Nifedipine ErNifedipine | 278 | $9,090 |
| Bumetanide | 118 | $5,376 |
| Potassium Citrate ErPotassium Citrate | 29 | $4,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $202,613 | $291,353257 claims |
| Fresenius USA Marketing, Inc.Velphoro | $34,483 | $217,62977 claims |
| BayerKerendia | $115,926 | $211,869186 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $191 | $49,01316 claims |
| Boehringer IngelheimJardiance | $21 | $35,57626 claims |
| Akebia Therapeutics IncAuryxia | $51,790 | $30,93231 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $73,002 | $1,00429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Beaufort
- Martin WebbBeaufort$66K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Mohammed AlzubaidiSumter$54K
- Joshua LipschutzCharleston$44K
- Renee EllisColumbia$40K
- Charles BunkeCharleston$39K
- Anand AchantiCharleston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.